[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,072,038
  • Shares Outstanding, K 115,821
  • Annual Sales, $ 655,350 K
  • Annual Income, $ -136,230 K
  • EBIT $ -116 M
  • EBITDA $ -162 M
  • 60-Month Beta 0.90
  • Price/Sales 2.97
  • Price/Cash Flow N/A
  • Price/Book 5.89

Options Overview Details

View History
  • Implied Volatility 69.12% (+1.56%)
  • Historical Volatility 93.35%
  • IV Percentile 47%
  • IV Rank 19.66%
  • IV High 152.45% on 03/18/26
  • IV Low 48.72% on 06/06/25
  • Expected Move (DTE 5) 1.28 (7.13%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,985
  • Volume Avg (30-Day) 1,254
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 31,750
  • Open Int (30-Day) 29,412
  • Expected Range 16.62 to 19.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 4
  • High Estimate $-0.23
  • Low Estimate $-0.47
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.40 +72.02%
on 04/13/26
18.19 -1.65%
on 05/08/26
+7.10 (+65.80%)
since 04/08/26
3-Month
9.82 +82.18%
on 02/09/26
18.19 -1.65%
on 05/08/26
+7.75 (+76.43%)
since 02/06/26
52-Week
9.82 +82.18%
on 02/09/26
20.06 -10.82%
on 05/29/25
+0.45 (+2.58%)
since 05/08/25

Most Recent Stories

More News
NovoCure: Q1 Earnings Snapshot

NovoCure: Q1 Earnings Snapshot

NVCR : 17.89 (+6.30%)
Novocure Reports First Quarter 2026 Financial Results

Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced...

NVCR : 17.89 (+6.30%)
NovoCure's Narrowing Losses Could Signal a Turning Point for Optune Adoption

Barchart Research What to Expect from NVCR Earnings NVCR Generated April 29, 2026 Current Price $11.93 EPS Estimate $$-0.40 Consensus Rating Moderate Buy Average Move 8.34% NovoCure's Narrowing Losses...

NVCR : 17.89 (+6.30%)
Novocure to Report First Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...

NVCR : 17.89 (+6.30%)
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ® ), ...

NVCR : 17.89 (+6.30%)
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure to launch Optune Lua in Japan with national reimbursement coverage

NVCR : 17.89 (+6.30%)
Novocure to Participate in 2026 Leerink Global Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann,...

NVCR : 17.89 (+6.30%)
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 17.89 (+6.30%)
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax ® approved by the U.S. FDA for the...

NVCR : 17.89 (+6.30%)
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients

NVCR : 17.89 (+6.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 19.78
2nd Resistance Point 18.98
1st Resistance Point 18.44
Last Price 17.89
1st Support Level 17.10
2nd Support Level 16.30
3rd Support Level 15.76

See More

52-Week High 20.06
Last Price 17.89
Fibonacci 61.8% 16.15
Fibonacci 50% 14.94
Fibonacci 38.2% 13.73
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.